In agreement, the reduction of P-AKT in KRAS-mutant Capan-1 human cancer cells stably induced with PIP5K1A sgRNA was reversed upon expressing wild-type PIP5K1A, but not a PIP5K1AKM mutant45 in which the presumptive catalytic site was mutated (Fig. 4d). This evidence concerns the gene KRAS and cancer.